Open label phase III safety, efficacy, and pharmacokinetic study of NABI-IGIV [immunoglobulins] 10% [immune globulin intravenous (human)] in subjects with primary immune deficiency disorders (PIDD)

Trial Profile

Open label phase III safety, efficacy, and pharmacokinetic study of NABI-IGIV [immunoglobulins] 10% [immune globulin intravenous (human)] in subjects with primary immune deficiency disorders (PIDD)

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Immunoglobulin G (Primary)
  • Indications Immunodeficiency disorders
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 11 Apr 2012 Primary endpoint 'Infection-rate' has been met, according to a Biotest AG media release.
    • 11 Apr 2012 Results were published in the Journal of Clinical Immunology, according to a Biotest AG media release.
    • 23 Mar 2012 Company (Biotest Pharmaceuticals) added as trial sponsor, additional lead trial centre and investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top